Embryo Selection Prediction Market: 100,000-by-2030 Odds Hit 25% on Manifold

Morgan Reeves
July 26, 2026
7 min read

The offbeat prediction market everyone is suddenly betting on: will 100,000 people be conceived with the help of advanced embryo selection by 2030. On Manifold, traders put the implied probability of YES at 25% as of July 26, 2026, after a busy 24 hours that drew 139 unique bettors. There is no single breaking headline behind the move. Instead, the market is riding a year-long surge of coverage, controversy, and commercial expansion around trait-based embryo screening

Google · Preferred Sources

Don’t miss new tech stories on Google

Add Tech Insider once in the Google app and our stories appear in your news suggestions

Add Now

What this market is actually asking

The contract lives on Manifold, a play-money prediction platform where users trade with a virtual currency called mana rather than real dollars. The question is blunt: “Will over 100,000 people be conceived with the help of advanced embryo selection techniques by 2030?” A YES resolution requires a cumulative count of more than 100,000 conceptions attributed to those techniques before the decade turns

Because Manifold runs on mana, this is not a regulated financial instrument like a Kalshi event contract or a Polymarket position. It is closer to a structured opinion poll with skin in the game. That distinction matters for how much weight to put on the number, and we return to it below

The odds, and what 25% implies

As of July 26, 2026, the market prices YES at roughly 25% implied probability the crowd thinks it is about three times more likely than not that the 100,000 threshold will not be crossed by 2030. That is a skeptical but not dismissive reading. If you want a refresher on how a market price maps to a percentage chance, see our explainer on implied probability and how yes and no shares are priced

The 24-hour signal is what pushed this contract onto the radar. It logged top-tier volume for the day on itsche science question, that level of participation is unusual and typically reflects fresh attention rather than a slow drift

What is driving the move

We could not verify a single discrete event from the past one to two weeks that mechanically moved this contract. The most-supported explanation is broader: 2026 has been a breakout year for embryo-selection coverage, and this question is a natural lightning rod for that attention

The clearest catalyst earlier in the year was editorial. In January 2026, MIT Technology Review named embryo scoring one of its 10 Breakthrough Technologies for 2026, noting that testing had become available through a growing number of US fertility clinics. That kind of framing tends to seed downstream debate for months, and it did

Then came the ethics pushback. Around the turn of 2026, the American Society for Reproductive Medicine’s Ethics and Practice Committees released a report concluding that polygenic embryo screening, known as PGT-P, is not ready for clinical use and should not be offered as a routine reproductive service given predictive uncertainty and unresolved ethical questions. In May 2026, NPR ran a widely shared piece on companies that let parents try to pick their babies’ traits, keeping the topic in general circulation. Each wave of coverage feeds curiosity markets like this one.

Who and what is involved

The commercial field is small and named. Genomic Prediction introduced the first clinical PGT-P application in 2019. Orchid Health, based in Palo Alto, later offered more comprehensive sequencing focused on health risk. In 2025, two newer entrants, Herasight and Nucleus Genomics, expanded the trait claims well beyond disease risk to include predictions for height, body mass index, longevity, and cognitive traits

Nucleus Genomics, led by founder Kian Sadeghi, drew the loudest response. Its embryo product, priced around $5,999, lets parents upload genetic data from up to 20 embryos and ranks them across a long list of projected traits. Bioethicists Arthur Caplan and James Tabery publicly argued that the marketing oversells what the science supports. In Scientific American, critics called the idea of “optimizing” embryos misleading, unethical, and not currently achievable at the level advertised

There is also litigation. In October 2025, Genomic Prediction filed a federal trade-secret lawsuit in New Jersey against former employee Nathan Treff, a colleague, and Nucleus Genomics, alleging misappropriation tied to its LifeView sequencing platform. In November 2025, a district judge denied Genomic Prediction’s motion for a preliminary injunction, finding it had not shown a likelihood of success at that stage. The underlying case continues

The measurement problem the market cannot escape

The single biggest reason for skepticism is definitional. “Advanced embryo selection techniques” is not a standardized category with a public counter attached to it. It could mean narrow polygenic screening like PGT-P, or AI-based embryo scoring, or the far more common PGT-A test for chromosomal abnormalities, or time-lapse imaging, or nearly any modern IVF lab workflow

No authoritative body currently publishes a cumulative tally of people “conceived with the help of” these methods. If the definition is narrow, real numbers today are modest and a 2030 crossing looks hard. If the definition is broad enough to include routine PGT-A during IVF, the count is plausibly far larger, but nobody reports it in a single standardized figure. A market can only resolve cleanly if the resolver picks a definition, and that ambiguity is a live risk for anyone trading it. This is a common failure mode in thin markets, and it is one reason understanding how a market maker prices these contracts is useful before you read too much into a single number.

Does the clinical evidence support a step change?

Not yet, at least not decisively. A 2024 randomized, double-blind trial published in Nature Medicine found that a deep-learning embryo-selection system did not demonstrate noninferiority to standard morphology-based selection for clinical pregnancy, though it cut assessment time roughly tenfold. In May 2026, MIT Technology Review described a broader shift toward AI, automation, and expanded PGT use, while framing the frontier tools as promising rather than proven. The through line across the credible literature is adoption and commercialization outpacing hard outcome data.

A timeline of the 2026 embryo-selection story

Context for a tech and finance reader

Curiosity markets like this one are less a forecast than a sentiment gauge. On a play-money venue, prices can be moved by a single motivated trader or a burst of social sharing, so treat 25% as a rough consensus rather than a precise probability. For comparison, real-money exchanges route order flow differently, which is one reason we track them separately in pieces like how political prediction markets work and our look at another viral Manifold contract. If you also follow real-money venues, our primer on what Kalshi is lays out the regulated side of the industry.

The financial subtext is real even if the market is playful. Investor money has flowed into direct-to-consumer genetic testing, and reporting has tied high-profile technology figures to funding rounds in the sector. That capital, plus clinic-level expansion of testing, is exactly why a 100,000-by-2030 question feels plausible enough to attract bets, and why the ambiguity around definitions keeps the price from running away

What to watch next

Three things would move this contract meaningfully. First, any standardized public count of conceptions tied to advanced selection, which would turn a fuzzy question into a measurable one. Second, regulatory action in the US or abroad, since a ban or a green light changes adoption curves quickly. Third, a landmark clinical result showing selection improves live-birth outcomes, which would accelerate uptake and push the count toward the threshold. Absent those, expect the price to track news cycles more than fundamentals.

Is this a real-money market? No. It trades on Manifold using mana, a virtual currency. It is not a regulated financial contract, so read the 25% as sentiment, not as a dollar-weighted forecast

Why did it spike on July 26, 2026? No single verified event triggered it. The most-supported explanation is sustained 2026 coverage of trait-based embryo selection, including MIT Technology Review’s January breakthrough pick and follow-on features, drawing curious traders

What counts as “advanced embryo selection”? The market does not define it precisely. It could span polygenic screening, AI embryo scoring, or routine PGT-A. That ambiguity is the biggest resolution risk

Does the science support crossing 100,000 by 2030? It is unclear. Adoption is rising, but recent trials show mixed outcome benefits, and no authoritative

The Bottom Line

A niche Manifold contract put the odds of 100,000 people being conceived with advanced embryo selection by 2030 at 25% as of July 26, 2026, on top-tier daily volume from 139 bettors. The move reflects a year of intense coverage and commercial expansion, not a single news event, and the question’s vague definition makes it as much a debate about measurement as about biology. Treat the number as a sentiment reading on a fast-moving, contested field.

Sources

• Manifold — Will over 100,000 people be conceived with the help of advanced embryo selection techniques by 2030?
• MIT Technology Review — Embryo scoring: 10 Breakthrough Technologies 2026
• ASRM — Polygenic Embryo Screening Is Not Ready for Clinical Use
• NPR — These labs say they can screen embryos for specific traits. Should you?
• Scientific American — Why Genetically Optimizing Embryos Is Misleading, Unethical, and Not Even Possible
• MIT Technology Review — What’s next for IVF
• Manatt — Court denies Genomic Prediction injunction against Nucleus

Prediction markets carry risk and are not investment or betting advice. Availability is restricted by jurisdiction: Polymarket is not available to US persons, and Kalshi is a CFTC-regulated US exchange. Manifold is a play-money platform. Age limits of 18+ or 21+ apply where relevant. If gambling is a problem for you or someone you know, call 1-800-GAMBLER for confidential help